On July 25, 2023, Robert Wilson, President and director of Immune Therapeutics, Inc. d/b/a Biostax Corp., delivered a letter of resignation to the Company, pursuant to which Mr. Wilson resigned as President of the Company, effective immediately. Mr. Wilson?s resignation was not the result of any material dispute or disagreement on any matter relating to the operations, policies, or practices of the Company. Kelly Wilson was appointed President of the Company effective July 25, 2023.

Ms. Wilson, age 52, served as Chief Executive Officer of the Company from April 2023 to July 2023, as Chief Operating Officer of the Company since August 2022, and as Interim President and Interim Chief Executive Officer of the Company from November 2022 to April 2023. From 2013 to April 2020, Ms. Wilson was the Company?s Chief Technology Officer. From September 2014 to April 2020, Ms. Wilson also served as Chief Technology and Information Officer of Cytocom, Inc. prior to its merger with Cleveland BioLabs, Inc., now known as Statera Biopharma, Inc. (OTC Expert Market: STAB), a clinical-stage biopharmaceutical company and former subsidiary of the Company.

From April 2020 to April 2022, Ms. Wilson was also Director of Program and Project Management of Statera Biopharma, Inc. From May 2022 to July 2022, Ms. Wilson was Chief Operating Officer of Biostax, Inc., an immunotherapy startup. Ms. Wilson graduated with honors from the University of Central Florida with a master?s degree in systems design and a bachelor?s degree in English.